Pharmacogenetic Profiling of Cytochrome P450 Enzymes in Plasmodium vivax Patients Treated with Chloroquine and Primaquine: Implications for Personalized Malaria Therapy

This study aimed to investigate the impact of common polymorphisms in key cytochrome P450 (CYP) genes (CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A5) on drug levels and treatment responses in Plasmodium vivax-infected patients treated with chloroquine (CQ) and primaquine (PQ). CYP2C8 and CYP3A5 are the key enzymes that metabolize CQ, whereas CYP2D6, CYP2C9, and CYP2C19 are those that metabolize PQ. A total of 99 DNA samples from Burmese patients with microscopically confirmed P. vivax monoinfection, who received standard doses of CQ (25 mg/kg) and PQ (15 mg/kg/day for 14 days), were included for genotyping of CYP polymorphisms using polymerase chain reaction-restriction fragment length polymorphism assays. The relationship between CYP polymorphisms and patients' clinical outcomes and drug level data was assessed. All patients achieved complete parasite clearance and resolution of fever without recurrence. The most frequent alleles were CYP3A5*3 (71.7%) and CYP2D6*10 (30.6%). The CYP3A5*3 variant was significantly associated with altered desethylchloroquine levels, whereas CYP2C19*3 was associated with faster parasite clearance. No significant associations were found between CYP2D6 or CYP2C8 variants and PQ levels or clinical efficacy. Notably, a patient homozygous for CYP2D6*4 (a poor metabolizer) responded successfully to treatment, suggesting the presence of alternative or compensatory metabolic pathways. Despite a high prevalence of reduced-function CYP variants, CQ-PQ therapy was effective in all patients, indicating that genetic polymorphisms may influence drug metabolism without compromising clinical outcomes. Nevertheless, CYP3A5*3 and CYP2C19*3 variants appear to modulate drug pharmacokinetics and parasite clearance kinetics. These findings underscore the importance of pharmacogenetic surveillance to optimize antimalarial therapy, particularly in elimination settings.

Authors

Institutions

Publication Details

Journal
American Journal of Tropical Medicine and Hygiene
Published
2026-02-12
DOI
https://doi.org/10.4269/ajtmh.25-0612
Primary Topic
Malaria Research and Control
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pharmacogenetic Profiling of Cytochrome P450 Enzymes in Plasmodium vivax Patients Treated with Chloroquine and Primaquine: Implications for Personalized Malaria Therapy

Anurak Cheoymang, Papichaya Phompradit, Phunuch Muhamad, Kesara Na-Bangchang
American Journal of Tropical Medicine and Hygiene
Malaria Research and Control
article

Pharmacogenetic Profiling of Cytochrome P450 Enzymes in Plasmodium vivax Patients Treated with Chloroquine and Primaquine: Implications for Personalized Malaria Therapy

Anurak Cheoymang, Papichaya Phompradit, Phunuch Muhamad, Kesara Na-Bangchang
article en

Abstract

This study aimed to investigate the impact of common polymorphisms in key cytochrome P450 (CYP) genes (CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A5) on drug levels and treatment responses in Plasmodium vivax-infected patients treated with chloroquine (CQ) and primaquine (PQ). CYP2C8 and CYP3A5 are the key enzymes that metabolize CQ, whereas CYP2D6, CYP2C9, and CYP2C19 are those that metabolize PQ. A total of 99 DNA samples from Burmese patients with microscopically confirmed P. vivax monoinfection, who received standard doses of CQ (25 mg/kg) and PQ (15 mg/kg/day for 14 days), were included for genotyping of CYP polymorphisms using polymerase chain reaction-restriction fragment length polymorphism assays. The relationship between CYP polymorphisms and patients' clinical outcomes and drug level data was assessed. All patients achieved complete parasite clearance and resolution of fever without recurrence. The most frequent alleles were CYP3A5*3 (71.7%) and CYP2D6*10 (30.6%). The CYP3A5*3 variant was significantly associated with altered desethylchloroquine levels, whereas CYP2C19*3 was associated with faster parasite clearance. No significant associations were found between CYP2D6 or CYP2C8 variants and PQ levels or clinical efficacy. Notably, a patient homozygous for CYP2D6*4 (a poor metabolizer) responded successfully to treatment, suggesting the presence of alternative or compensatory metabolic pathways. Despite a high prevalence of reduced-function CYP variants, CQ-PQ therapy was effective in all patients, indicating that genetic polymorphisms may influence drug metabolism without compromising clinical outcomes. Nevertheless, CYP3A5*3 and CYP2C19*3 variants appear to modulate drug pharmacokinetics and parasite clearance kinetics. These findings underscore the importance of pharmacogenetic surveillance to optimize antimalarial therapy, particularly in elimination settings.

American Journal of Tropical Medicine and Hygiene
Thammasat University (TH), Hodges University (US)
Good health and well-being
Openalex Percentile: Top 60%
Malaria Research and Control
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Pharmacogenetic Profiling of Cytochrome P450 Enzymes in Plasmodium vivax Patients Treated with Chloroquine and Primaquine: Implications for Personalized Malaria Therapy — Anurak Cheoymang, Papichaya Phompradit, et al. · American Journal of Tropical Medicine and Hygiene (2026) | TGRS Research Map | TGRS